128 related articles for article (PubMed ID: 12511745)
1. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study.
Huxley RR; Hawkins MH; Humphries SE; Karpe F; Neil HA;
Stroke; 2003 Jan; 34(1):22-5. PubMed ID: 12511745
[TBL] [Abstract][Full Text] [Related]
2. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.
Atherosclerosis; 1999 Jan; 142(1):105-12. PubMed ID: 9920511
[TBL] [Abstract][Full Text] [Related]
3. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
Neil HA; Hawkins MM; Durrington PN; Betteridge DJ; Capps NE; Humphries SE;
Atherosclerosis; 2005 Apr; 179(2):293-7. PubMed ID: 15777544
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
Neil HA; Huxley RR; Hawkins MM; Durrington PN; Betteridge DJ; Humphries SE;
Atherosclerosis; 2003 Sep; 170(1):73-8. PubMed ID: 12957684
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.
Kjærgaard KA; Christiansen MK; Schmidt M; Olsen MS; Jensen HK
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28652386
[TBL] [Abstract][Full Text] [Related]
6. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.
BMJ; 1991 Oct; 303(6807):893-6. PubMed ID: 1933004
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013.
Mundal L; Igland J; Ose L; Holven KB; Veierød MB; Leren TP; Retterstøl K
Eur J Prev Cardiol; 2017 Jan; 24(2):137-144. PubMed ID: 27794106
[TBL] [Abstract][Full Text] [Related]
8. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
Neil A; Cooper J; Betteridge J; Capps N; McDowell I; Durrington P; Seed M; Humphries SE
Eur Heart J; 2008 Nov; 29(21):2625-33. PubMed ID: 18840879
[TBL] [Abstract][Full Text] [Related]
9. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry.
Alonso R; Díaz-Díaz JL; Arrieta F; Fuentes-Jiménez F; de Andrés R; Saenz P; Ariceta G; Vidal-Pardo JI; Almagro F; Argueso R; Prieto-Matos P; Miramontes JP; Pintó X; Rodriguez-Urrego J; Perez de Isla L; Mata P
J Clin Lipidol; 2016; 10(4):953-961. PubMed ID: 27578128
[TBL] [Abstract][Full Text] [Related]
11. Identification of familial hypercholesterolemia in Taiwan: report of eleven cases.
Chung MH; Chen KW; Chen JF; Lu WT; Sun JH; Lin JD
Changgeng Yi Xue Za Zhi; 1999 Sep; 22(3):460-7. PubMed ID: 10584419
[TBL] [Abstract][Full Text] [Related]
12. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
13. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).
Pérez de Isla L; Alonso R; Mata N; Fernández-Pérez C; Muñiz O; Díaz-Díaz JL; Saltijeral A; Fuentes-Jiménez F; de Andrés R; Zambón D; Piedecausa M; Cepeda JM; Mauri M; Galiana J; Brea Á; Sanchez Muñoz-Torrero JF; Padró T; Argueso R; Miramontes-González JP; Badimón L; Santos RD; Watts GF; Mata P
Circulation; 2017 May; 135(22):2133-2144. PubMed ID: 28275165
[TBL] [Abstract][Full Text] [Related]
14. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
Ojala JP; Helve E; Karjalainen K; Tarkkanen A; Tikkanen MJ
Atherosclerosis; 1990 May; 82(1-2):85-95. PubMed ID: 2360923
[TBL] [Abstract][Full Text] [Related]
15. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
[TBL] [Abstract][Full Text] [Related]
16. Higher incidence of mild cognitive impairment in familial hypercholesterolemia.
Zambón D; Quintana M; Mata P; Alonso R; Benavent J; Cruz-Sánchez F; Gich J; Pocoví M; Civeira F; Capurro S; Bachman D; Sambamurti K; Nicholas J; Pappolla MA
Am J Med; 2010 Mar; 123(3):267-74. PubMed ID: 20193836
[TBL] [Abstract][Full Text] [Related]
17. Familial hypercholesterolemia: stroke and the broader perspective.
Meschia JF
Stroke; 2003 Jan; 34(1):22-5. PubMed ID: 12511735
[No Abstract] [Full Text] [Related]
18. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy.
Raal FJ; Pilcher GJ; Panz VR; van Deventer HE; Brice BC; Blom DJ; Marais AD
Circulation; 2011 Nov; 124(20):2202-7. PubMed ID: 21986285
[TBL] [Abstract][Full Text] [Related]
19. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
Meuwese MC; de Groot E; Duivenvoorden R; Trip MD; Ose L; Maritz FJ; Basart DC; Kastelein JJ; Habib R; Davidson MH; Zwinderman AH; Schwocho LR; Stein EA;
JAMA; 2009 Mar; 301(11):1131-9. PubMed ID: 19293413
[TBL] [Abstract][Full Text] [Related]
20. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P;
Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
